T2DH34.SA Teladoc Health Inc.
- Market cap
- BRL 9.67B
- P/E
- -
- P/B
- 1.24x
- ROE
- -13.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is T2DH34.SA undervalued?
Graham numberThe Graham number of Teladoc Health Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Teladoc Health Inc. fundamental analysis
No fundamental analysis for Teladoc Health Inc. yet.
Teladoc Health Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Teladoc Health Inc.
Teladoc Health, Inc. provides virtual healthcare services worldwide. It operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical services, specialty medical, chronic condition management, and mental health services, as well as technologies and enterprise telehealth solutions for hospitals and health systems. Its BetterHelp segment operates a mental health pl…
Full company profileTeladoc Health Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Teladoc Health Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 418M | 553M | 1.09B | 2.03B | 2.41B | 2.60B | 2.57B | 2.53B | 2.43B |
| Gross Profit | 289M | 369M | 703M | 1.38B | 1.66B | 1.84B | 1.82B | 1.76B | 1.66B |
| Operating Income | -66.0M | -73.8M | -418M | -239M | -13.7B | -249M | -1.02B | -263M | -140M |
| EBITDA | -35.3M | -35.5M | -437M | -84.7M | -13.4B | 151M | -587M | 161M | 225M |
| Net Income | -97.1M | -98.9M | -485M | -429M | -13.7B | -220M | -1.00B | -200M | -173M |
| EPS | -1.38 | -1.36 | -3.23 | -2.67 | -84 | -1.32 | -5.77 | -1.12 | -0.95 |
| Balance Sheet | |||||||||
| Total Assets | 1.53B | 1.60B | 17.8B | 17.7B | 4.35B | 4.39B | 3.52B | 2.86B | 2.78B |
| Total Liabilities | 516M | 589M | 1.87B | 1.69B | 2.04B | 2.07B | 2.03B | 1.47B | 1.48B |
| Shareholders' Equity | 1.01B | 1.01B | 15.9B | 16.0B | 2.31B | 2.33B | 1.49B | 1.39B | 1.29B |
| Cash & Short-term Investments | 424M | 514M | 787M | 896M | 918M | 1.12B | 1.30B | 781M | 850M |
| Cash Flow | |||||||||
| Operating Cash Flow | -4.86M | 29.9M | -53.5M | 194M | 189M | 350M | 294M | 294M | 241M |
| Capital Expenditure | 4.01M | 3.51M | 4.02M | 8.53M | 173M | 156M | 124M | 157M | 144M |
| Free Cash Flow | -13.3M | 19.0M | -79.6M | 130M | 16.5M | 194M | 170M | 137M | 96.9M |
| Ratios | |||||||||
| ROE | -9.6% | -9.7% | -3.1% | -2.7% | -591.9% | -9.5% | -67.1% | -14.5% | -13.4% |
| ROA | -6.4% | -6.2% | -2.7% | -2.4% | -314.3% | -5.0% | -28.5% | -7.0% | -6.2% |
| Net Profit Margin | -23.2% | -17.9% | -44.3% | -21.1% | -567.5% | -8.5% | -39.0% | -7.9% | -7.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Teladoc Health Inc. dividends
Teladoc Health Inc. has not paid dividends in the last 8 fiscal years.
Last stock split: 0.033333:1 on Apr 6, 2026.
Who owns Teladoc Health Inc.
Ownership data of Teladoc Health Inc. is not available yet.
Teladoc Health Inc. company profile
- Company name
- Teladoc Health Inc.
- Ticker
- T2DH34.SA
- Exchange
- Sao Paulo Exchange
- Sector
- Healthcare
- Industry
- Health Care Technology
- Employees
- 4,648
- Fiscal year end
- December
- Address
- 155 E 44th Street, New York, NY, United States, 10017
- Phone
- 203 635 2002
- Website
- teladochealth.com
About Teladoc Health Inc.
Teladoc Health, Inc. provides virtual healthcare services worldwide. It operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical services, specialty medical, chronic condition management, and mental health services, as well as technologies and enterprise telehealth solutions for hospitals and health systems. Its BetterHelp segment operates a mental health platform that provides online counselling and therapy services through websites, mobile applications, phones, and text-based interactions by its licensed clinicians. The company offers its products and services under the Teladoc and BetterHelp brands. It serves employers, health plans, hospitals and health systems, insurance companies, and financial services companies, as well as individual members. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was incorporated in 2002 and is headquartered in New York, New York.
Teladoc Health Inc. management
10- Mr. Charles Divita III, CPACEO & Director · born 1970
- Mr. Adam Christian Vandervoort J.D.Chief Legal Officer & Secretary · born 1975
- Mr. Carlos NuenoPresident of International · born 1974
- Ms. Kelly M. BlissPresident of U.S. Group Health · born 1975
- Dr. George Byron Brooks BS EE, M.D.Co-Founder
- Mr. Michael Fitzgerald GrasherChief Financial Officer · born 1965
- Mr. Joseph Ronald Catapano CpaSenior VP & Chief Accounting Officer · born 1969
- Mr. Dave RossChief Technology Officer
- Michael MinchakVice President of Investor Relations
- Ms. Valerie HaertelInvestor Relations Officer